Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 18.46M P/E - EPS this Y 70.10% Ern Qtrly Grth -
Income -34.36M Forward P/E -1.42 EPS next Y 3.90% 50D Avg Chg -17.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -17.00%
Dividend N/A Price/Book 0.84 EPS next 5Y - 52W High Chg -62.00%
Recommedations 1.70 Quick Ratio 2.79 Shares Outstanding 10.74M 52W Low Chg 1.00%
Insider Own 14.87% ROA -176.03% Shares Float 4.55M Beta -
Inst Own 53.22% ROE - Shares Shorted/Prior 37.17K/20.82K Price 3.26
Gross Margin - Profit Margin - Avg. Volume 28,300 Target Price 16.38
Oper. Margin - Earnings Date May 13 Volume 10,005 Change -0.91%
About CalciMedica, Inc.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors, used for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

CalciMedica, Inc. News
07:00 AM CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis
03/28/24 CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
03/13/24 CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
02/28/24 CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference
02/13/24 CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury
02/07/24 CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
01/22/24 CalciMedica Announces Private Placement of up to Approximately $55 Million
12/11/23 CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition
11/09/23 CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
11/02/23 CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
09/06/23 CalciMedica Announces Upcoming Presentations and Events in September
08/31/23 CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023
08/10/23 CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
08/09/23 CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
06/12/23 CalciMedica Announces Relisting on Nasdaq
06/06/23 CalciMedica Announces Publication of Preclinical Data in Journal of Clinical Investigation (JCI) Insight Supporting the Development of CRAC Channel Inhibitors for Chronic Pancreatitis (CP)
05/23/23 CalciMedica Expands Executive Team with New Appointments
05/15/23 CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
CALC Chatroom

User Image Stock_Titan Posted - 1 hour ago

$CALC CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis https://www.stocktitan.net/news/CALC/calci-medica-announces-last-patient-enrolled-in-phase-2b-carpo-trial-ntvcbf8dspwd.html

User Image insiderbuyingselling Posted - 3 weeks ago

$CALC new insider buying: 4000 shares. http://insiderbuyingselling.com/?t=CALC

User Image colombian2c Posted - 03/31/24

$CALC is this shit dead or what ?

User Image Stock_Titan Posted - 03/28/24

$CALC CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates https://www.stocktitan.net/news/CALC/calci-medica-reports-2023-financial-results-and-provides-clinical-7j0kkc2i9tae.html

User Image RallyRaider Posted - 4 weeks ago

$CALC love hearing "paradigm" has lots of promising data pending 1h 2024 and insiders/institutions really liked the offering-- who knows more??

User Image MrAlientrader Posted - 1 month ago

$CALC no retailers interested in this stock

User Image JayQueline Posted - 1 month ago

$CALC I put my hand into the cookie jar one too many times and now Mama has slammed the lid onto my hand. The $$ I made trading in an out of this is almost gone. So I will be out near B/E. At least I didn't lose my shirt on this one.

User Image JayQueline Posted - 1 month ago

$CALC The data presentation appears to be good but that's what they needed to keep this price range. Now that the news is out, the market makers have decided to jump ship and move on to something else they can pump and dump. This has dropped about $1 in less than a weeks time and is now sitting in the mid $3s. I figure there is more pressure that will be places on this stock to push it into the $2s or under. This things is done for a long time now.

User Image RedDogSailor Posted - 1 month ago

$CALC I’ve been holding this for years since it was Gray something. I had no idea it’s been so heavily shorted for a very long time.

User Image Multan101 Posted - 1 month ago

$CALC something good or bad news

User Image JayQueline Posted - 1 month ago

$CALC LIking the news https://www.stocktitan.net/news/CALC/calci-medica-presents-data-from-preclinical-studies-of-auxora-in-jlcubpx2y7my.html

User Image RAPIDTRADX Posted - 1 month ago

$CALC 👀

User Image Stock_Titan Posted - 1 month ago

$CALC CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference https://www.stocktitan.net/news/CALC/calci-medica-presents-data-from-preclinical-studies-of-auxora-in-jlcubpx2y7my.html

User Image TimingTimingTiming Posted - 1 month ago

$CALC Long. I love the thin liquidity. Any good news and this thing blows up imo

User Image Multan101 Posted - 1 month ago

$CALC any good news

User Image realestateguy Posted - 02/28/24

$CALC we have news let see how this plays out

User Image Stock_Titan Posted - 02/28/24

$CALC CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference https://www.stocktitan.net/news/CALC/calci-medica-announces-presentation-of-data-from-a-preclinical-study-l1yvqjyc76dz.html

User Image Multan101 Posted - 02/27/24

$CALC any good news

User Image Quantumup Posted - 2 months ago

Singular Research raised PT $CALC $9.5 was $6.25/Buy-Venture: New funding adds some timing certainty to CalciMedica’s highest pipeline priorities. Additional cash may also provide more negotiating leverage for a future potential partnership. Data readout by end of H1:24 will be primary investor focus. Recent funding increases our confidence level that management can execute on its key pipeline timelines. We adjust our projections to reflect cash infusion, revenue forecast increase, and lower rate expectations. Reiterating our Buy-Venture rating and raising our target price to $9.50, from $6.25. JonesTrading~02/15/24~🏁initiated $CALC Buy/$22: CalciMedica is a clinical-stage biotech focused on inhibition of calcium release-activated calcium channels. Jones estimates 20% peak mkt penetration, in acute pancreatitis of $370M in WW peak sales. With multiple shots on goal in severe inflammatory diseases, Jones is bullish on the shares over the next 12-18 months.

User Image Multan101 Posted - 2 months ago

$CALC what happen

User Image HaltTradeAlert Posted - 2 months ago

$CALC Halt Time: 09:30:16 Issue Symbol: CALC Reason Code: LUDP Stock Price: $4.5100 Market Cap: 46.26M Volume: 42,084 Relative Volume: 2.89 Shares Float: 2.41M Get this alert real time and sent to your phone just like a text by going to our website and joining our community for FREE! We just launched this service! Help us spread the word ! www.HaltTradeAlert.com

User Image realestateguy Posted - 2 months ago

$CALC

User Image Ninja_Tradez Posted - 2 months ago

📢 $CALC -JonesTrading Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $22 https://newsfilter.io/a/90416b6cf103821d93eadf66ab75d5f0

User Image realestateguy Posted - 2 months ago

$CALC come on!!

User Image realestateguy Posted - 2 months ago

$CALC we down today. Hope it bounce back

User Image realestateguy Posted - 2 months ago

$CALC

User Image DaleZGT500 Posted - 2 months ago

$CALC PT $17.00

User Image TheTradeXchange Posted - 2 months ago

$CALC - CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

User Image Stock_Titan Posted - 2 months ago

$CALC CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury https://www.stocktitan.net/news/CALC/calci-medica-announces-fda-clearance-of-ind-application-for-phase-2-8d793arq5isu.html

User Image XavierLawlor1 Posted - 2 months ago

$CALC $BMR $IHRT Analyst price target for next week>> https://profitable-trading-community.daytrading.network

Analyst Ratings
Oppenheimer Outperform Apr 1, 24
HC Wainwright & Co. Buy Apr 1, 24
HC Wainwright & Co. Buy Mar 13, 24
JonesTrading Buy Feb 16, 24
HC Wainwright & Co. Buy Feb 13, 24
HC Wainwright & Co. Buy Jan 29, 24
Oppenheimer Outperform Nov 13, 23
EF Hutton Buy Jul 7, 23
EF Hutton Buy Jun 20, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MIDDLETON FRED A Director Director Jan 23 Buy 3.7 679,384 2,513,721 30,292 01/25/24
Sanderling Venture Partners VI... Director Director Jan 23 Buy 3.7 679,384 2,513,721 30,292 01/25/24
WILSON ROBERT N Director Director Dec 11 Buy 3.30 506 1,670 182,161 12/13/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Nov 07 Buy 3.34 2,000 6,680 18,840 11/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Nov 06 Buy 3.12 2,400 7,488 35,894 11/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Nov 03 Buy 2.8 14,949 41,857 33,494 11/07/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Nov 06 Buy 3.1208 2,440 7,615 16,840 11/07/23
Hebbar Sudarshan Chief Medical Office.. Chief Medical Officer Nov 03 Buy 2.7389 36,000 98,600 46,000 11/07/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Aug 25 Buy 3.02 223 673 5,223 09/05/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Aug 21 Buy 3.26 2,464 8,033 4,264 08/23/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 23 Buy 3.53 1,900 6,707 13,387 06/26/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 08 Buy 5.225 1,000 5,225 9,000 06/15/23
MIDDLETON FRED A Director Director Jun 09 Buy 5.20 714 3,713 11,714 06/09/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 08 Buy 5.20 485 2,522 13,185 06/09/23
MIDDLETON FRED A Director Director Jun 06 Buy 5.04 1,000 5,040 11,000 06/08/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 06 Buy 5.16 4,700 24,252 12,700 06/08/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 06 Buy 5.19 2,000 10,380 8,000 06/08/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer Jun 02 Buy 4.80 1,000 4,800 6,000 06/05/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 16 Buy 2.698 1,000 2,698 1,000 06/05/23
Roberts Eric W Chief Business Offic.. Chief Business Officer Jun 01 Buy 4.66 3,687 17,181 12,187 06/05/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 31 Buy 4.21 1,000 4,210 5,000 06/01/23
BJERKHOLT ERIC Director Director May 30 Buy 3.85 255 982 3,684 06/01/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 30 Buy 3.8616 2,000 7,723 8,000 06/01/23
BJERKHOLT ERIC Director Director May 23 Buy 3.268 500 1,634 3,429 05/24/23
Leheny A. Rachel Chief Executive Offi.. Chief Executive Officer May 23 Buy 3.3439 3,000 10,032 4,000 05/24/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 22 Buy 3.11 8,000 24,880 8,500 05/24/23
BJERKHOLT ERIC Director Director May 16 Buy 2.69 1,300 3,497 2,729 05/18/23
Hebbar Sudarshan Chief Medical Office.. Chief Medical Officer May 16 Buy 2.6999 10,000 26,999 10,000 05/18/23
Roberts Eric W Chief Business Offic.. Chief Business Officer May 16 Buy 2.7 8,300 22,410 1,800 05/18/23
BREUIL ROBERT S Chief Financial Offi.. Chief Financial Officer Mar 31 Sell 1.25 2,188 2,735 20,529 04/04/22